Eli Lilly and Co (BSP:LILY34) Current Accrued Expense : R$57,274 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Eli Lilly and Co Current Accrued Expense?

Eli Lilly and Co's Current Accrued Expense for the quarter that ended in Dec. 2023 was R$57,274 Mil.

Eli Lilly and Co's quarterly Current Accrued Expense increased from Jun. 2023 (R$50,429 Mil) to Sep. 2023 (R$56,905 Mil) and increased from Sep. 2023 (R$56,905 Mil) to Dec. 2023 (R$57,274 Mil).

Eli Lilly and Co's annual Current Accrued Expense increased from Dec. 2021 (R$38,712 Mil) to Dec. 2022 (R$46,076 Mil) and increased from Dec. 2022 (R$46,076 Mil) to Dec. 2023 (R$57,274 Mil).

Eli Lilly and Co Current Accrued Expense Historical Data

The historical data trend for Eli Lilly and Co's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Current Accrued Expense Chart

Eli Lilly and Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

20,249.96

30,111.93

38,712.31

46,076.12

57,273.76

Eli Lilly and Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial															46,076.12	49,635.35	50,429.46	56,905.18	57,273.76

Eli Lilly and Co Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Eli Lilly and Co Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Eli Lilly and Co (BSP:LILY34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (BSP:LILY34) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

LLY:USA LLY:Mexico 1LLY:Italy LLY:Germany LLY:Switzerland LLY:Canada LLYC:Austria LLY:Argentina

Address

Lilly Corporate Center, Indianapolis, IN, USA, 46285

Website

https://www.lilly.com

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (BSP:LILY34) Headlines

No Headlines